Every day at CIRM we get calls from people looking for a stem cell therapy to help them fight a life-threatening or life-altering disease or condition. One of the most common calls is about osteoarthritis, a painful condition where the cartilage that helps cushion our joints is worn away, leaving bone to rub on bone. People call asking if we have something, anything, that might be able to help them. Now we do.
At yesterday’s CIRM Board meeting the Independent Citizens’ Oversight Committee or ICOC (the formal title of the Board) awarded almost $8.5 million to the California Institute for Biomedical Research (CALIBR) to test a drug that appears to help the body regenerate cartilage. In preclinical tests the drug, KA34, stimulated mesenchymal stem cells to turn into chondrocytes, the kind of cell found in healthy cartilage. It’s hoped these new cells will replace those killed off by osteoarthritis and repair the damage.
This is a Phase 1 clinical trial where the goal is primarily to make sure this approach is safe in patients. If the treatment also shows hints it’s working – and of course we hope it will – that’s a bonus which will need to be confirmed in later stage, and larger, clinical trials.
From a purely selfish perspective, it will be nice for us to be able to tell callers that we do have a clinical trial underway and are hopeful it could lead to an effective treatment. Right now the only alternatives for many patients are powerful opioids and pain killers, surgery, or turning to clinics that offer unproven stem cell therapies.
Targeting immune system cancer
The CIRM Board also awarded Poseida Therapeutics $19.8 million to target multiple myeloma, using the patient’s own genetically re-engineered stem cells. Multiple myeloma is caused when plasma cells, which are a type of white blood cell found in the bone marrow and are a key part of our immune system, turn cancerous and grow out of control.
As Dr. Maria Millan, CIRM’s President & CEO, said in a news release:
“Multiple myeloma disproportionately affects people over the age of 65 and African Americans, and it leads to progressive bone destruction, severe anemia, infectious complications and kidney and heart damage from abnormal proteins produced by the malignant plasma cells. Less than half of patients with multiple myeloma live beyond 5 years. Poseida’s technology is seeking to destroy these cancerous myeloma cells with an immunotherapy approach that uses the patient’s own engineered immune system T cells to seek and destroy the myeloma cells.”
In a news release from Poseida, CEO Dr. Eric Ostertag, said the therapy – called P-BCMA-101 – holds a lot of promise:
“P-BCMA-101 is elegantly designed with several key characteristics, including an exceptionally high concentration of stem cell memory T cells which has the potential to significantly improve durability of response to treatment.”
The third clinical trial funded by the Board yesterday also uses T cells. Researchers at Children’s Hospital of Los Angeles were awarded $4.8 million for a Phase 1 clinical trial targeting potentially deadly infections in people who have a weakened immune system.
Viruses such as cytomegalovirus, Epstein-Barr, and adenovirus are commonly found in all of us, but our bodies are usually able to easily fight them off. However, patients with weakened immune systems resulting from chemotherapy, bone marrow or cord blood transplant often lack that ability to combat these viruses and it can prove fatal.
The researchers are taking T cells from healthy donors that have been genetically matched to the patient’s immune system and engineered to fight these viruses. The cells are then transplanted into the patient and will hopefully help boost their immune system’s ability to fight the virus and provide long-term protection.
Whenever you can tell someone who calls you, desperately looking for help, that you have something that might be able to help them, you can hear the relief on the other end of the line. Of course, we explain that these are only early-stage clinical trials and that we don’t know if they’ll work. But for someone who up until that point felt they had no options and, often, no hope, it’s welcome and encouraging news that progress is being made.
8 thoughts on “CIRM Board invests in three new stem cell clinical trials targeting arthritis, cancer and deadly infections”
I would like to be involved in a stem cell OA study. I am a very fit 61 year old athlete and wish to avoid a knee replacement (no insurance and possible complications with a replacement).
Hi Doug. Our Agency is funding a clinical trial for osteoarthritis sponsored by the California Institute for Biomedical Research. The trial is not currently enrolling patients, but it will be soon. You can contact the institute for further information and visit clinicaltrials.gov to learn more about the trial. Here is the link
I had three containers of stem cells put into my back and my knee six injections in my back two in my knee. It’s been three weeks , still no difference. Should I be getting some relief by now?
Dear Sharon, I am afraid that’s a question you have to pose to the people who gave you the stem cells. Part of the problem with getting therapies that have not been approved by the FDA is that we have no way of knowing how quickly they should begin to kick in and offer relief.
I would like to get into a clinical trials for stem cell research I have arthritis rheumatoid and osteoarthritis in many joints doc meds are not working I have been living with these issues more than 20years the doctor meds are not working I feel stem cell research would do my body good
Dear Kevin, I am so sorry to hear about your health problems. I can only imagine how challenging that must be. We are funding a clinical trial that is targeting osteoarthritis in the knee. If you are interested in learning more about that work here is a link to the page on the http://www.clinicaltrials.gov website that has more information on eligibility and how you can apply:
I do hope that helps.
Can I get a stem cell transplant in the US to treat caebv?
Hi Mark, I’m afraid I wasn’t able to find any stem cell therapy for CAEBV.